NCT02630186: A trial that was reported late by Clovis Oncology, Inc.
This trial has reported, although it was 57 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02630186 |
|---|---|
| Title | A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Feb. 24, 2016 |
| Completion date | Sept. 5, 2017 |
| Required reporting date | Sept. 5, 2018, midnight |
| Actual reporting date | Nov. 1, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 57 |